The first GLP-1 drug, a copy of a Gila monster venom peptide, approved for type 2 diabetes in 2005. The brands are discontinued in the US.
Also called Byetta, Bydureon, Bydureon BCise, exendin-4, synthetic exendin-4, generic exenatide
When Exenatide's status or evidence changes, it's in the next morning's email.
Exenatide is a synthetic copy of exendin-4, a 39-amino-acid peptide found in the venom of the Gila monster lizard. It activates the same receptor as human GLP-1. In 2005 it became the first GLP-1 drug approved by FDA, as Byetta, a twice-daily injection for type 2 diabetes. A once-weekly version in slow-release microspheres followed as Bydureon (2012) and the Bydureon BCise autoinjector (2017).
The effect on blood sugar is real but smaller than newer drugs. In DURATION-1, 295 people lowered HbA1c by 1.9 points on weekly exenatide vs 1.5 points on the twice-daily form over 30 weeks. Weight loss is a few kilograms: 2.8 kg over 30 weeks on Byetta 10 mcg in an early metformin trial. In EXSCEL, 14,752 people with type 2 diabetes took weekly exenatide or placebo for a median 3.2 years. Major heart events were 11.4% vs 12.2%, which showed the drug was safe for the heart but did not prove it protects it.
AstraZeneca discontinued Byetta (October 25, 2024) and Bydureon BCise (October 28, 2024) in the US. Amneal's generic twice-daily exenatide, approved in November 2024, is the version still on the US market. Exenatide also had a run as a Parkinson's disease candidate, but the 194-person phase 3 trial published in 2025 found no slowing of the disease.
What it binds to, and what happens inside the body after that, step by step.
Exenatide binds and activates the GLP-1 receptor. It raises insulin release when blood sugar is high, lowers glucagon after meals, slows stomach emptying and reduces appetite. The twice-daily form works mainly on the meals it is injected before; the weekly form keeps a steady level.
Human results and animal results are kept apart below. A result in rats tells you a mechanism is plausible. It does not tell you what happens in a person.
Exenatide has hundreds of human trials, including the DURATION program and the EXSCEL outcome trial. It lowers HbA1c by roughly 0.8 to 1.9 points and weight by a few kilograms. EXSCEL showed heart safety but missed its goal of proving fewer heart events. Brain claims have not held up: the phase 3 Parkinson's trial was negative.
14,752 adults with type 2 diabetes, 73% with prior heart disease
Heart attack, stroke or cardiovascular death occurred in 11.4% on exenatide 2 mg weekly vs 12.2% on placebo over a median 3.2 years (hazard ratio 0.91); safe, but superiority was not shown (p=0.06).
Read the study295 adults with type 2 diabetes
HbA1c fell 1.9 points on 2 mg weekly vs 1.5 points on 10 mcg twice daily at 30 weeks; 77% vs 61% reached HbA1c of 7% or less.
Read the study336 adults with type 2 diabetes on metformin
HbA1c fell 0.78 points on 10 mcg twice daily vs a 0.08 rise on placebo; weight fell 2.8 kg.
Read the study194 adults with Parkinson's disease in the UK
After 96 weeks, motor scores off medication worsened by 5.7 points on exenatide vs 4.5 on placebo, with no difference between groups.
Read the study62 adults with moderate Parkinson's disease
Off-medication motor scores were 3.5 points better than placebo at 60 weeks, a result the larger phase 3 trial did not confirm.
Read the studyNo preclinical studies are listed as key studies here. The human data above carries the evidence.
When a new Exenatide study in people is published, the daily email covers it.
These are questions the published research has not answered.
Prescription-only. Drugs@FDA lists Byetta, Bydureon, the Bydureon pen and Bydureon BCise as discontinued; AstraZeneca notified FDA that it stopped Byetta on October 25, 2024 and Bydureon BCise on October 28, 2024. FDA approved Amneal's generic exenatide pen (referencing Byetta) in November 2024, the first generic in the GLP-1 class. Not on the WADA Prohibited List and not in WADA's Monitoring Program. Unlike other GLP-1 drugs, the twice-daily form carries no boxed thyroid warning, while the weekly forms do.
When the FDA or WADA changes Exenatide's status, it's in the next morning's email.
How much of Exenatide is left after a single dose
Simple first-order model from the published half-life. Real clearance varies with dose, route, kidney and liver function and formulation. This is not a dosing schedule.
This table records the doses that trials and approved labels used, with the source for each row. It is a record of research, not a recommendation, and it is open to free members.
Which symptoms are expected and which mean stop and get help: side effects and red flags.
Tap a claim to see what the studies found.
Close. Exendin-4 was isolated from Gila monster venom in 1992. The drug is made synthetically; no lizards are involved in production.
A 62-person trial in 2017 looked promising, but the 194-person phase 3 trial published in 2025 found motor scores worsened just as much on exenatide as on placebo over 96 weeks.
EXSCEL found 11.4% vs 12.2% major heart events, a difference that was not statistically significant. It proved heart safety, not heart protection.
AstraZeneca discontinued both Byetta and Bydureon BCise in October 2024. Generic twice-daily exenatide from Amneal remains available.
These pairings come up often. Almost none have been tested together in a trial, and the evidence note on each says so plainly.
Both slow stomach emptying and reduce appetite, through different receptors (GLP-1 and amylin).
EvidenceNo approved combination product, and we found no large trial of the pair. Combining two drugs that slow the stomach raises nausea and low-blood-sugar risk.
Sometimes proposed to add effect.
EvidenceNever studied together. The labels advise against combining exenatide products, and other GLP-1 drugs act on the same receptor.
The discontinued Bydureon BCise was an extended-release microsphere suspension in a prefilled autoinjector: store flat in the fridge at 36 to 46 F (2 to 8 C), protected from light, and up to 4 weeks at room temperature not above 86 F (30 C).
Generic twice-daily exenatide pens: refrigerate at 36 to 46 F (2 to 8 C) before first use; after first use keep at or below 77 F (25 C); do not freeze, protect from light, and discard 30 days after first use.
One email when a trial reads out, a label changes or the FDA acts on a peptide. Free, every source linked, unsubscribe any time.